Pregledni rad

https://doi.org/10.20471/acc.2019.58.01.19

Fertility Preservation in Young Women with Early-Stage Breast Cancer

Petra Vuković ; Division of Radiotherapy and Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia
Miro Kasum ; Department of Obstetrics and Gynecology, Zagreb University Hospital Centre, Zagreb, Croatia
Jelena Raguž ; Division of Radiotherapy and Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia
Nikolina Lonjak ; Division of Radiotherapy and Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia
Sara Bilić Knežević ; Zadar General Hospital, Department of Oncology and Nuclear Medicine, Zadar, Croatia
Ivana Orešković ; School of Medicine, University of Zagreb, Zagreb, Croatia
Lidija Beketić Orešković ; Division of Radiotherapy and Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia; Department of Clinical Oncology, School of Medicine, University of Zagreb, Zagreb, Croatia
Ermin Čehić ; Human Reproduction Unit, Zenica Cantonal Hospital, Zenica, Bosnia and Herzegovina

Sažetak

Although breast cancer (BC) occurs more often in older women, it is the most commonly diagnosed malignancy in women of childbearing age. Owing to the overall advancement of modern medicine and the growing global trend of delaying childbirth until later age, we find ever more younger women diagnosed and treated for BC who have not yet completed their family. Therefore, fertility preservation has emerged as a very important quality of life issue for young BC survivors. This paper reviews currently available options for fertility preservation in young women with earlystage BC and highlights the importance of a multidisciplinary approach to fertility preservation as a very important quality of life issue for young BC survivors. Pregnancy after BC treatment is considered not to be associated with an increased risk of BC recurrence; therefore, it should not be discouraged for those women who want to achieve pregnancy after oncologic treatment. Currently, it is recommended to delay pregnancy for at least 2 years after BC diagnosis, when the risk of recurrence is highest. However, BC patients of reproductive age should be informed about the potential negative
effects of oncologic therapy on fertility, as well as on the fertility preservation options available, and if interested in fertility preservation, they should be promptly referred to a reproductive specialist. Early
referral to a reproductive specialist is an important factor that increases the likelihood of successful fertility preservation. Embryo and mature oocyte cryopreservation are currently the only established fertility preservation methods but they require ovarian stimulation (OS), which delays initiation of chemotherapy for at least 2 weeks. Controlled OS does not seem to increase the risk of BC recurrence. Other fertility preservation methods (ovarian tissue cryopreservation, cryopreservation of immature oocytes and ovarian suppression with gonadotropin-releasing hormone agonists) do not require OS but are still considered to be experimental techniques for fertility preservation.

Ključne riječi

Fertility preservation – methods; Breast neoplasms; Cryopreservation – methods; Ovulation, induction; Gonadotropin-releasing hormone – agonists; Quality of Life

Hrčak ID:

220907

URI

https://hrcak.srce.hr/220907

Datum izdavanja:

1.3.2019.

Podaci na drugim jezicima: hrvatski

Posjeta: 3.203 *